BioInvent Announces Publication of Preclinical and Early Phase 1 Data for BI-1607 in HER2-Positive Advanced Solid Tumors
LUND, SE / ACCESS Newswire / November 18, 2025 / BioInvent International (STO:BINV): Most (78%) patients experienced disease control (stable disease), including heavily pretreated individuals with HER2-positive breast and gastric cancers A favorable clinical safety profile and early signs of efficacy further support the potential of FcγRIIB-blocking monoclonal antibodies in multiple solid tumors BioInvent remains […]